Botulinum toxin type A and cervical dystonia: A seven-year follow-up;Toxina botulínica a e distonia cervical: Avaliação após sete anos

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 5, 2011, Pages 745-750

  Camargo, Carlos Henrique F ^a   Teive, Hélio Afonso G ^a   Becker, Nilson ^a   Munhoz, Renato P ^a   Werneck, Lineu César ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Botulinum toxin; Cervical dystonia; Dysphagia

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CERVICAL DYSTONIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DYSPHAGIA; FEMALE; FOLLOW UP; HEMIDYSTONIA; HUMAN; IDIOPATHIC DISEASE; MALE; MEDICAL RECORD; MOTOR PERFORMANCE; MULTIFOCAL DYSTONIA; OROMANDIBULAR DYSTONIA; PAIN; RATING SCALE; SEGMENTAL DYSTONIA; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; VISUAL ANALOG SCALE;

EID: 80455127105     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000600004     Document Type: Article

References (25)

1. Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984; 2: 541-554.
2. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ 3rd. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-194.
3. Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC. Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr 2008;66:15-21.
4. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121:547-560.
5. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-247.
6. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13:433-444.
7. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-280.
8. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999;246:265-274.
9. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-1293.
10. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1988;38:530-532.
11. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-836.
12. Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 2005;12: 163-170.
13. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 2004;19:303-308.
14. Erbguth F, Claus D, Jaspert A, Druschky A, Neundorfer B. Which patients discontinue treatment with botulinum toxin in cervical dystonia? Mov Disord 1995;10:37.
15. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.
16. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998;50:1461-1463.
17. Maia FM, Kanashiro AK, Chien HF, Gonçalves LR, Barbosa ER. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 2010;16:8-11.
18. Godeiro-Junior C, Felício AC, Aguiar PM, Borges V, Silva SM, Ferraz HB. Retrocollis, anterocollis or head tremor may predict the spreading of dystonic movements in primary cervical dystonia. Arq Neuropsiquiatr 2009; 67:402-406.
19. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-126.
20. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-791.
21. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
22. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17.
23. Wan X, Tang X. Comparison of Botox and a Chinese type a botulinum toxin in cervical dystonia. Zhonghua Yi Xue Za Zhi 1998;78:131-134.
24. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol 2010;33:22-26.
25. Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007;29:1325-1337.